levofloxacin has been researched along with sitafloxacin in 38 studies
| Studies (levofloxacin) | Trials (levofloxacin) | Recent Studies (post-2010) (levofloxacin) | Studies (sitafloxacin) | Trials (sitafloxacin) | Recent Studies (post-2010) (sitafloxacin) |
|---|---|---|---|---|---|
| 4,346 | 581 | 2,209 | 16 | 0 | 3 |
| 4,346 | 581 | 2,209 | 185 | 22 | 85 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (26.32) | 18.2507 |
| 2000's | 14 (36.84) | 29.6817 |
| 2010's | 12 (31.58) | 24.3611 |
| 2020's | 2 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Baroni, M; Cecchetti, V; Cianchetta, G; Cruciani, G; Mannhold, R | 1 |
| Black, JA; Hanson, ND; Hong, SG; Hossain, A; Moland, ES; Thomson, KS; Wickman, PA | 1 |
| Aubry, A; Cambau, E; Jarlier, V; Matrat, S; Petrella, S; Sougakoff, W | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Hibi, T; Muraoka, H; Nishizawa, T; Suzuki, H | 1 |
| Fujioka, T; Hasegawa, M; Ikeda, F; Kobayashi, I; Kodama, M; Murakami, K; Muraoka, H; Okimoto, T; Saika, T; Takigawa, M; Tanahashi, J | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Hamasuna, R; Jensen, JS; Osada, Y | 1 |
| Hakanen, AJ; Huovinen, P; Kotilainen, P; Lehtopolku, M; Nakari, UM; Siitonen, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Bera, S; Mondal, D | 1 |
| Cormican, MG; Jones, RN; Marshall, SA | 1 |
| Bale, MJ; Erwin, ME; Jones, RN | 1 |
| Houston, AK; Jones, RN | 1 |
| Hayakawa, I; Hohmura, M; Hoshino, K; Ishida, H; Kitamura, A; Nishino, T; Sato, K; Tanaka, M | 1 |
| Hecht, DW; Wexler, HM | 1 |
| Goldstein, EJ | 1 |
| Inui, KI; Ito, T; Tanaka, K; Yano, I | 1 |
| Izumi, K; Kawazoe, K; Mikamo, H; Sato, Y; Tamaya, T | 1 |
| Giamarellos-Bourboulis, EJ; Giamarellou, H; Grecka, P; Sambatakou, H | 1 |
| Akaki, T; Kajitani, H; Kawahara, S; Sakatani, M; Sato, K; Tomioka, H | 1 |
| Cai, S; Kamei, T; Ogasawara, K; Sano, C; Sano, K; Sato, K; Shimizu, T; Tomioka, H | 1 |
| Hoshino, K; Ishida, H; Ishida, Y; Kawato, H; Kurosaka, Y; Lee, VJ; Nakayama, K; Ohta, T; Ohtsuka, M; Otani, T; Renau, TE; Watkins, WJ; Yokomizo, Y; Yoshida, K | 1 |
| Dawe, RS; Ferguson, J; Ibbotson, SH; Sanderson, JB; Thomson, EM | 1 |
| Akamine, M; Fujita, J; Haranaga, S; Higa, F; Nakasone, C; Nakasone, I; Shinzato, T; Tateyama, M; Touyama, M; Yamane, N | 1 |
| Izumikawa, K; Kakeya, H; Kamihira, S; Kohno, S; Morinaga, Y; Nakamura, S; Seki, M; Yamamoto, Y; Yanagihara, K | 1 |
| Hori, S | 1 |
| Higuchi, W; Imamura, Y; Kanda, H; Nishiyama, A; Takano, T; Taneike, I; Yamamoto, T; Yoshida, K | 1 |
| Berning, M; Krasz, S; Labenz, J; Miehlke, S; Morgner, A | 1 |
| Chen, X; Guo, X; Shi, G; Wang, H; Wang, S; Zhang, X | 1 |
| Malithong, A; Phiboonbanakit, D; Santiwatanakul, S; Srisangchan, P; Srisurat, N; Susaengrat, W; Tantisiriwat, W; Thamlikitkul, V; Thunyaharn, S; Tiengrim, S | 1 |
| Amagai, K; Ando, T; Asaka, M; Furuta, T; Hori, S; Inaba, T; Inoue, S; Inui, Y; Iwamoto, J; Kamoshida, T; Kato, M; Kodama, M; Kudo, M; Mabe, K; Miwa, J; Mizuno, S; Murakami, K; Nakajima, T; Nomura, H; Ohkusa, T; Okimoto, T; Oshima, T; Sasaki, M; Satoh, K; Suganuma, T; Take, S; Tomita, T; Tomokane, T; Yamamoto, S | 1 |
| Ang, TL; Song, M | 1 |
| Hoshino, K; Kohno, S; Kurosaka, Y; Morinaga, Y; Nagaoka, K; Yanagihara, K | 1 |
| Deguchi, T; Hatazaki, K; Ito, S; Kondo, H; Mizutani, K; Nakane, K; Nakano, M; Ohinishi, M; Shimuta, K; Tsuchiya, T; Yasuda, M; Yokoi, S | 1 |
| Hashimoto, J; Hirose, T; Hiyama, Y; Hotta, H; Ichihara, K; Itoh, N; Kunishima, Y; Masumori, N; Matsukawa, M; Tachiki, H; Taguchi, K; Takahashi, S; Takeyama, K; Uehara, T; Yanase, M | 1 |
| Guo, S; Li, X; Li, Y; Shao, J; Tian, M; Tong, H; Wei, M; Xu, B; Yan, B | 1 |
| Aozasa, N; Fukano, H; Ishii, N; Miyamoto, Y; Murakami, T; Nakamura, K; Tsunemi, Y | 1 |
4 review(s) available for levofloxacin and sitafloxacin
| Article | Year |
|---|---|
Insights of synthetic analogues of anti-leprosy agents.
Topics: Humans; Leprostatic Agents; Leprosy; Structure-Activity Relationship | 2019 |
Possible role for the new fluoroquinolones (levofloxacin, grepafloxacin, trovafloxacin, clinafloxacin, sparfloxacin, and DU-6859a) in the treatment of anaerobic infections: review of current information on efficacy and safety.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Bacterial Infections; Fluoroquinolones; Humans; Levofloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolones; Safety; Syndrome | 1996 |
[Current value of quinolones in Helicobacter pylori therapy].
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2011 |
Second and third line treatment options for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Moxifloxacin; Ofloxacin; Rifabutin; Rifamycins; Rifaximin; Salvage Therapy; Virulence Factors | 2014 |
2 trial(s) available for levofloxacin and sitafloxacin
| Article | Year |
|---|---|
A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity.
Topics: Adult; Anti-Bacterial Agents; Asian People; China; Dermatitis, Phototoxic; Dose-Response Relationship, Drug; Drug Administration Schedule; Enoxacin; Female; Fluoroquinolones; Follow-Up Studies; Humans; Japan; Levofloxacin; Light; Male; Middle Aged; Ofloxacin; Scotland; Single-Blind Method; Skin Tests; Statistics, Nonparametric; White People | 2003 |
Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan.
Topics: Aged; Amoxicillin; Anti-Ulcer Agents; Drug Resistance; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Japan; Lansoprazole; Levofloxacin; Male; Middle Aged; Treatment Outcome | 2013 |
32 other study(ies) available for levofloxacin and sitafloxacin
| Article | Year |
|---|---|
Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach.
Topics: Anti-Bacterial Agents; Enterococcus faecalis; Escherichia coli; Models, Molecular; Pseudomonas aeruginosa; Quantitative Structure-Activity Relationship; Quinolones; Staphylococcus aureus; Thermodynamics | 2004 |
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
Topics: Drug Resistance, Bacterial; Drug Resistance, Microbial; Fluoroquinolones; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Microbial Sensitivity Tests; Quinolones | 2007 |
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
Topics: Anti-Infective Agents; DNA; DNA Gyrase; DNA, Superhelical; Enzyme Inhibitors; Mycobacterium leprae; Quinolones; Topoisomerase II Inhibitors | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Sitafloxacin and garenoxacin may overcome the antibiotic resistance of Helicobacter pylori with gyrA mutation.
Topics: Anti-Infective Agents; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Helicobacter pylori; Mutation | 2009 |
Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations.
Topics: Anti-Bacterial Agents; DNA Gyrase; Fluoroquinolones; Helicobacter pylori; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
Topics: Microbial Sensitivity Tests; Mycoplasma genitalium; Polymerase Chain Reaction | 2009 |
Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
Topics: Anti-Bacterial Agents; Campylobacter coli; Campylobacter Infections; Campylobacter jejuni; Carbapenems; Drug Resistance, Multiple, Bacterial; Erythromycin; Feces; Finland; Humans; Macrolides; Microbial Sensitivity Tests; Minocycline; Tigecycline | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin).
Topics: Anti-Infective Agents; Bacteria, Aerobic; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Fleroxacin; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Quinolones; Spiro Compounds | 1995 |
Minimum inhibitory concentration quality-control guidelines for biapenem, DU-6859a, FK-037, levofloxacin, grepafloxacin, and ceftizoxime when using various National Committee for Clinical Laboratory Standards susceptibility test methods. Quality Control S
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Bacteria; Ceftizoxime; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Piperazines; Quality Control; Quinolones; Reference Values; Spiro Compounds; Thienamycins | 1994 |
Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin.
Topics: Anti-Infective Agents; Bacteria; Enterococcus faecalis; Escherichia coli; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus | 1994 |
Effect of growth conditions on antimicrobial activity of DU-6859a and its bactericidal activity determined by the killing curve method.
Topics: Anti-Infective Agents; Cell Division; Ciprofloxacin; Culture Media; Culture Media, Serum-Free; Drug Resistance, Microbial; Escherichia coli; Fluoroquinolones; Humans; Hydrogen-Ion Concentration; Kinetics; Levofloxacin; Metals; Microbial Sensitivity Tests; Microscopy, Electron; Ofloxacin; Pseudomonas aeruginosa; Quinolones; Staphylococcus aureus; Urine | 1996 |
In vitro susceptibility of anaerobes to quinolones in the United States.
Topics: Anti-Infective Agents; Bacteria, Anaerobic; Culture Media; Drug Resistance, Microbial; Evaluation Studies as Topic; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Piperazines; Quinolones; United States | 1996 |
Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1.
Topics: Animals; Anti-Infective Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Daunorubicin; Epithelial Cells; Epithelium; Fluoroquinolones; Humans; Kidney; Levofloxacin; LLC-PK1 Cells; Ofloxacin; Quinolones; Swine | 1997 |
Therapeutic effects of a new quinolone, DU-6859a, on polymicrobial infections in a newly designed model of rat uterine endometritis.
Topics: Animals; Anti-Infective Agents; Bacteroides fragilis; Disease Models, Animal; Drug Therapy, Combination; Endometritis; Escherichia coli; Female; Fluoroquinolones; Levofloxacin; Ofloxacin; Quinolones; Rats; Rats, Sprague-Dawley | 1998 |
In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Enterococcus faecalis; Enterococcus faecium; Fluoroquinolones; Gentamicins; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Quinolones; Virginiamycin | 1998 |
Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Topics: Anti-Infective Agents; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium tuberculosis; Ofloxacin; Quinolones | 1999 |
Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines.
Topics: Anti-Infective Agents; Antibiotics, Antitubercular; Cell Line; Epithelial Cells; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Macrophages; Mycobacterium tuberculosis; Ofloxacin; Pulmonary Alveoli | 2003 |
MexAB-OprM specific efflux pump inhibitors in Pseudomonas aeruginosa. Part 2: achieving activity in vivo through the use of alternative scaffolds.
Topics: Animals; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Biological Transport, Active; Carrier Proteins; Drug Resistance, Microbial; Fluoroquinolones; Gene Expression Regulation, Bacterial; Lactams; Levofloxacin; Membrane Transport Proteins; Mice; Microbial Sensitivity Tests; Neutropenia; Ofloxacin; Protein Binding; Pseudomonas aeruginosa; Rats; Sepsis; Serum Albumin; Structure-Activity Relationship | 2003 |
In vitro activity of sitafloxacin against clinical strains of Streptococcus pneumoniae with defined amino acid substitutions in QRDRs of gyrase A and topoisomerase IV.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Bacterial Proteins; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Ofloxacin; Sequence Analysis, DNA; Streptococcus pneumoniae | 2006 |
Comparative mutant prevention concentration and mutant selection window of sitafloxacin versus other quinolones using strains of Haemophilus influenzae with decreasing susceptibility to levofloxacin.
Topics: Adaptation, Biological; Anti-Bacterial Agents; Drug Resistance, Bacterial; Fluoroquinolones; Haemophilus influenzae; Humans; Levofloxacin; Mutation; Ofloxacin; Quinolones; Selection, Genetic | 2009 |
Convulsant activity of sitafloxacin and its interactions with anti-inflammatory drugs in mice.
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Dose-Response Relationship, Drug; Drug Interactions; Fluoroquinolones; Injections, Intraventricular; Levofloxacin; Mice; Ofloxacin; Seizures | 2009 |
Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Bacterial Agents; Drug Combinations; Fluoroquinolones; Gerbillinae; Helicobacter Infections; Helicobacter pylori; Lansoprazole; Levofloxacin; Male; Microbial Sensitivity Tests; Ofloxacin | 2011 |
Activity of sitafloxacin against extracellular and intracellular Staphylococcus aureus in vitro and in vivo: comparison with levofloxacin and moxifloxacin.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Cell Line; Chromatography, High Pressure Liquid; Disease Models, Animal; Dose-Response Relationship, Drug; Extracellular Space; Fluoroquinolones; Intracellular Space; Levofloxacin; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Peritonitis; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Time Factors | 2012 |
Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Respiratory Tract Infections; Thailand; Urinary Tract Infections | 2012 |
In vivo antianaerobe activity of DS-8587, a new fluoroquinolone, against Fusobacterium necrophorum in a mouse model.
Topics: Animals; Bacteria, Anaerobic; Disease Models, Animal; Fluoroquinolones; Fusobacterium necrophorum; Levofloxacin; Liver; Liver Abscess; Male; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests | 2017 |
Haemophilus influenzae Isolated From Men With Acute Urethritis: Its Pathogenic Roles, Responses to Antimicrobial Chemotherapies, and Antimicrobial Susceptibilities.
Topics: Acute Disease; Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Chlamydia Infections; Chlamydia trachomatis; Coinfection; Doxycycline; Drug Resistance, Bacterial; Fluoroquinolones; Gonorrhea; Haemophilus influenzae; Humans; Leukocyte Count; Levofloxacin; Male; Microbial Sensitivity Tests; Neisseria gonorrhoeae; Retrospective Studies; Urethritis | 2017 |
Selective culture of Escherichia coli to prevent infective complications of transrectal ultrasound-guided prostate biopsy: Clinical efficacy and analysis of characteristics of quinolone-resistant Escherichia coli.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Antibiotic Prophylaxis; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Humans; Image-Guided Biopsy; Japan; Levofloxacin; Logistic Models; Male; Microbial Sensitivity Tests; Prospective Studies; Prostate; Quinolones; Rectum; Treatment Outcome; Ultrasonography, Interventional | 2019 |
Sitafloxacin pharmacokinetics/pharmacodynamics against multidrug-resistant bacteria in a dynamic urinary tract infection in vitro model.
Topics: Anti-Bacterial Agents; Bacteria; Carbapenems; Escherichia coli; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Urinary Tract Infections; Vancomycin | 2022 |
Successful treatment of cutaneous Mycobacterium chelonae infection by switching from levofloxacin to sitafloxacin.
Topics: Anti-Bacterial Agents; Fluoroquinolones; Humans; Levofloxacin; Mycobacterium chelonae; Mycobacterium Infections; Mycobacterium Infections, Nontuberculous; Skin Diseases, Bacterial | 2023 |